



Psychedelics have recently become a topic of legal reform and intense commercial investment. In the past few years, dozens of cities and states have enacted or proposed legislation to decriminalize or regulate psychedelics. Our upcoming events programming will explore these developments and further implications.

Next Thursday, November 10th, attorneys with experience in cannabis and psychedelics law [will discuss what legislators, regulators, and professionals in the nascent psychedelics industry should learn from the successes and failures of cannabis regulation](#). The following week, on November 17th, psychedelic researchers will discuss the ethical codes and boundaries that are essential to ensure safe practices with these substances at our [panel discussion co-sponsored by the Chacruna Institute](#).

Also, on November 15th, we'll host an [event on the impact of violence against health care providers, current efforts being taken to ensure their safety, and next steps for reducing violence](#). Visit our [events page](#) to register for these events and keep up to date on new events!

Spotlight on Scholarship



**U.S. Eviction Policy is Harming Children:
The Case for Sustainable Eviction**

Prevention to Promote Health Equity

Without a nationwide commitment to sustainable eviction prevention, the United States will fail the rising number of renter households at risk of eviction.

[Read the full article.](#)

Upcoming Events

What Can the Psychedelics Industry Learn from Cannabis Regulation?

DATE

November 10, 2022, 12:30 PM, Online

Register for "What Can the Psychedelics Industry Learn from Cannabis Regulation?"

Violence in Healthcare: A Growing Crisis

DATE

November 15, 2022, 4 PM, Online

Register for "Violence in Healthcare"


Informed Consent in Psychedelic Therapy and Research: Why is it Complicated?

DATE

November 17, 2022, 3 PM, Online

Register for "Informed Consent in Psychedelic Therapy and Research"

Affiliate News and Scholarship



COVID-19 Coverage on Bill of Health:

["The Unfurling Crisis of Unfunded Isolation, Testing, and Treatment of Infectious Disease in the US,"](#) by Steven W. Thrasher.

“Accessing COVID-19 mRNA Vaccines for Research: The Re-emergence of the Tragedy of the ‘Anticommons,’” by Aparajita Lath.

“The Supreme Court Threatens to Undermine Vaccination Decisions Entrusted to the States,” by Donna Gitter.

“Sweet Land of Immunity,” by Teneille Brown.

“Using Legal Preparedness to Minimize Liability Barriers to Accessing Pandemic Vaccine and Medical Countermeasures,” by Ana Ayala, Anthony Brown, Emanuele Cesta, Katherine Ginsbach, Sam Halabi, and Dawn Mapatano.

“Liability for COVID-19 Vaccine Harms: We Need to Do Better,” by Dorit Reiss.



I. Glenn Cohen (Faculty Director)
@CohenProf

NEW SCHOLARSHIP

“The End of Anonymous Sperm Donation in Colorado: A Step Forward to a New Fertility Future in the US?” by I. Glenn Cohen, Eli Y. Adashi, and Seema Mohapatra in *JAMA*.

“Capping Prescription Drug Costs: State Initiatives to the Rescue?” by Eli Y. Adashi and I. Glenn Cohen in *Rhode Island Medical Journal*.

NEW COMMENTARY


“VIDEO: Dobbs abortion decision may require changes to reproductive medicine practice,” by Jill Rollet and I. Glenn Cohen in *Healio News*.



Holly Fernandez Lynch (Former Executive Director)
@HollyLynchez

NEW SCHOLARSHIP

“Perspectives of Academic Oncologists About Offering Expanded Access to Investigational Drugs,” by Patrick Gould, Tasnim Salam, Laura Kimberly, Alison Bateman-House, and Holly Fernandez Lynch in *JAMA Network Open*.



Alicia Ely Yamin (Senior Fellow in Global Health and Rights)
@AE_Yamin

PROFESSIONAL UPDATE

Alicia Ely Yamin named to the Editorial Review Board of the *Journal of Global Health Law*.

Mason Marks (Senior Fellow)
@MasonMarksMD



NEW COMMENTARY

“Seeking Psychedelics? Check the Data Privacy Clause,” by Mason Marks in *WIRED*.



Michael Ashley Stein (Affiliated Faculty)

NEW SCHOLARSHIP

“Supported decision-making can advance clinical research participation for people with disabilities,” by Benjamin C. Silverman, Ari Ne’eman, David H. Strauss, Willyanne DeCormier Plosky, Leslie P. Francis, Michael Ashley Stein, and Barbara E. Bierer in *Nature Medicine*.

“Excluding People With Disabilities From Clinical Research: Eligibility Criteria Lack Clarity And Justification,”

by Willyanne DeCormier Plosky, Ari Ne’eman, Benjamin C. Silverman, David H. Strauss, Leslie P. Francis, Michael A. Stein, and Barbara E. Bierer in *Health Affairs*.

“Nursing Home Residents Younger Than Age Sixty-Five Are Unique And Would Benefit From Targeted Policy Making.”

by Ari Ne’eman, Michael Stein, and David C. Grabowski in *Health Affairs*.



Rachel E. Sachs (Former Academic Fellow)

@RESachs

NEW COMMENTARY

“Medicare rejected a controversial Alzheimer’s drug. Participants still ended up paying for it,” by Lily Jamali, featuring Rachel Sachs in *Marketplace*.

“Preterm birth drug saga reflects concerns with FDA’s fast-track process,” by Caitlin Owens, featuring Rachel Sachs in *Axios*.

“Speedy FDA approvals in focus as agency weighs withdrawal of preterm birth drug,” by Jonathan Gardner and Christopher Newman, featuring Rachel Sachs in *Biopharma Dive*.

“Alnylam blames the Inflation Reduction Act for a PhIII cut – would it have sold enough for negotiations?” by Max Gelman and Zachary Brennan, featuring Rachel Sachs in *Endpoints News*.

“Updated: FDA explains why it won’t pull Jazz’s accelerated approval despite a failed confirmatory trial,” by Zachary Brennan, featuring Rachel Sachs in *Endpoints News*.

Selected Opportunity Listings

We choose a few upcoming opportunities to feature each week. To see [the full list, check our](#)

[site](#). To post your own, [get in touch!](#)



Online Roundtable: Advancements in Reproductive Care and Technology: Perspectives from Equality Law

Petrie-Flom Center | Harvard Law School, 23 Everett Street, Cambridge, MA 02138

[Unsubscribe petrie-flom@law.harvard.edu](mailto:unsubscribe@petrie-flom@law.harvard.edu)

[Update Profile](#) | [Constant Contact Data Notice](#)

Sent by petrie-flom@law.harvard.edu powered by



Try email marketing for free today!